©The Author(s) 2025.
Artif Intell Med Imaging. Sep 8, 2025; 6(2): 108032
Published online Sep 8, 2025. doi: 10.35711/aimi.v6.i2.108032
Published online Sep 8, 2025. doi: 10.35711/aimi.v6.i2.108032
Table 2 Positron emission tomography radiopharmaceuticals used with glioblastoma multiforme
| Biological processes | Radiotracer |
| Primary diagnosis-differential diagnosis–treatment planning and response | 18F-fluorodeoxyglucose (18F-FDG) |
| 11C-methyl-methionine (11C-MET) | |
| O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) | |
| 3,4-dihydroxy6-18F-fluoro-L-phenylalanine (18F-FDOPA) | |
| 18F-fluorotyrosine (18F-TYR) | |
| 18F-fluoromethyltyrosine (18F-FMT) | |
| 18F-fluorothymidine (18F-FLT) | |
| Tumor hypoxia | 18F-fluoromisonidazole (18F-FMISO) |
| 18F-fluoroazomycin-arabinozide (18F-FAZA) | |
| 18F-fluoroerythronitroimidazole (18F-FETNIM) | |
| 18F-2-nitroimidazol-pentafluoropropyl acetamide (18F-EF5) | |
| 18F-2-nitroimidazol-trifluoropropyl acetamide (18F-EF3) | |
| 18F-fluoroetanidazole (18F-FETA) | |
| 124I-iodoazomycin galactopyranoside (124I-IAZGP) | |
| 68Ga-labeled nitroimidazole analogs | |
| 60,61,62,64Cu-diacetyl-bis (N4-methylthiosemicarbazone (60,61,62,64Cu-ATSM) | |
| 124I-chimeric mAb G250 (124I-cG250) | |
| 89Zr-chimeric G250 F(ab′)2 (89Zr-cG250-F(ab′)2) | |
| Perfusion-membrane biosynthesis-proliferation rate | 13N-NH3 |
| 18F-fluorthymidine (18F-FLT) | |
| 18F-fluorocholine (18F-FCH) | |
| 15O-labeled water (15O-H2O) |
- Citation: Bentourkia M, Abdo RA. Updates on glioblastoma multiforme: From epidemiology to imaging and artificial intelligence. Artif Intell Med Imaging 2025; 6(2): 108032
- URL: https://www.wjgnet.com/2644-3260/full/v6/i2/108032.htm
- DOI: https://dx.doi.org/10.35711/aimi.v6.i2.108032